The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions

被引：0
作者：
Susan Hariri
Elizabeth R. Unger
Suzanne E. Powell
Heidi M. Bauer
Nancy M. Bennett
Karen C. Bloch
Linda M. Niccolai
Sean Schafer
Lauri E. Markowitz
机构：
[1] National Center for HIV,Division of STD Prevention
[2] Viral Hepatitis,Division of STD Prevention
[3] STD,Division of High
[4] and TB Prevention,Consequence Pathogens and Pathology
[5] Centers for Disease Control and Prevention,Center for Community Health and Department of Medicine
[6] National Center for HIV,Departments of Medicine and Preventive Medicine
[7] Viral Hepatitis,Division of Epidemiology of Microbial Diseases
[8] STD,undefined
[9] and TB Prevention,undefined
[10] Centers for Disease Control and Prevention,undefined
[11] National Center for Emerging and Zoonotic Infectious Diseases,undefined
[12] Centers for Disease Control and Prevention,undefined
[13] STD Control Branch,undefined
[14] California Department of Health,undefined
[15] University of Rochester School of Medicine and Dentistry,undefined
[16] Vanderbilt University Medical Center,undefined
[17] Yale School of Public Health,undefined
[18] HIV/STD/TB Program,undefined
[19] Division of STD,undefined
[20] Oregon Department of Human Services,undefined
来源：
Cancer Causes & Control | 2012年 / 23卷
关键词：
Human Papillomavirus (HPV); Cervical intraepithelial neoplasia (CIN); Cervical adenocarcinoma in situ (AIS); Post-licensure vaccine effectiveness; Vaccine impact; Surveillance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The following paper describes a collaboration between the Centers for Disease Control and Prevention and five Emerging Infections Program sites to develop a comprehensive population-based approach to monitoring human papillomavirus (HPV) vaccine impact on cervical cancer precursors and associated HPV genotypes. The process of establishing this novel monitoring system is described, and development details such as enumeration of sources for reporting cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ, approaches to case ascertainment, electronic reporting, and HPV typing are outlined. Implementation of a feasible and sustainable surveillance system for HPV-associated cervical precancers will enable evaluation of the direct impact of HPV vaccination.
引用
收藏
页码：281 / 288
页数：7
相关论文
共 86 条
[1]  
Watson M(2008)Burden of cervical cancer in the United States, 1998–2003 Cancer 113 2855-2864
[2]  
Saraiya M(2002)The causal relation between human papillomavirus and cervical cancer J Clin Pathol 55 244-265
[3]  
Benard V(2007)Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP) MMWR Recomm Rep 56 1-24
[4]  
Coughlin SS(2010)A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions MMWR 59 626-629
[5]  
Flowers L(2009)Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Cancer Prev Res (Phila) 2 868-878
[6]  
Cokkinides V(2009)Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods Lancet 374 301-314
[7]  
Schwenn M(2008)Human papillomavirus and cervical cancer Cancer 113 2841-2854
[8]  
Huang Y(2007)Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions Lancet 370 890-907
[9]  
Giuliano A(2007)Encouraging the right women to attend for cervical cancer screening: results from a targeted television campaign in Victoria, Australia N Engl J Med 356 1915-1927
[10]  
Bosch FX(2008)The role of the New South Wales Pap test register in monitoring the cervical screening process in New South Wales Health Educ Res 23 477-486
123456789